Model N enables life sciences and high tech companies to drive growth and market share, minimizing revenue leakage throughout the revenue lifecycle. With deep industry expertise and solutions purpose-built for these industries, Model N delivers comprehensive visibility, insight and control over the complexities of commercial operations and compliance. Our integrated cloud solution is proven to automate pricing, incentive and contract decisions to scale business profitably and grow revenue. Model N is trusted across more than 120 countries by the world’s leading pharmaceutical, medical technology, semiconductor, and high tech companies, including Johnson & Johnson, AstraZeneca, Stryker, Seagate Technology, Broadcom and Microchip Technology. For more information, visit www.modeln.com.
Location: United States, California, San Mateo
Employees: 501-1000
Phone: +1 650-610-4600
Founded date: 1999
Investors 1
| Date | Name | Website |
| - | LLR Partne... | llrpartner... |
Mentions in press and media 12
| Date | Title | Description |
| 18.05.2024 | Cyber security and artificial intelligence -- business value and risk | In the current era of digitalization, cybersecurity has become a topmost priority for businesses, regardless of their size and nature. With the growing dependence on digital infrastructure and data, safeguarding against cyber threats has be... |
| 08.04.2024 | Vista Equity Partners Acquires Model N for $1.25B | What You Should Know: – Model N (NYSE: MODN), a leading provider of revenue optimization and compliance solutions for the life sciences and high-tech industries, has announced a definitive agreement to be acquired by Vista Equity Partners (... |
| 08.04.2024 | Vista Equity to take revenue optimization platform Model N private in $1.25B deal | Model N, a platform used by companies such as Johnson & Johnson, AstraZeneca, and AMD to automate decisions related to pricing, incentives, and compliance, is going private in a $1.25 billion deal with private equity firm Vista Equity P... |
| 30.08.2013 | 4 ways pharma can deal with the unknowns of Obamacare | Pharma companies are overwrought with questions, some pertaining to pharma’s already tenuous relationship with the public. How will consumers perceive the “transfers of value” made from manufacturers to physicians? Still other questions inv... |
| 06.02.2013 | 15 things you should know about the final rule of the Physician Payment Sunshine Act | Back on December 19, 2011, CMS solicited public comment on the Physician Payment Sunshine Act, and in response, it received 373 comments. Since then pharmaceutical and medical device manufacturers have been waiting for the final rule, and l... |
| 28.01.2013 | 5 things you can do now to prepare for the Sunshine Act | Map all upstream aggregate spend activity. Start by mapping upstream activities along the aggregate spend continuum. While a complex and time-consuming exercise, this process takes advantage of this interim, waiting period to fill in the ga... |
| 02.01.2013 | 2013 forecast for the Sunshine Act: More waiting | One component of the Affordable Care Act that is of particular interest to medical device and pharmaceutical companies is the Physician Payment Sunshine Act (the Sunshine Act). For those who need a refresher, the act requires all manufactur... |
| 20.01.2012 | New location for NextFab Studios, computer center in Frankford [Links] | Soapy: an even better anti-SOPA browser plugin [boingboing] — From West Philly’s Griffin Boyce NextFab Studio is expanding from University City to a second location on Washington Avenue in South Philadelphia, NakedPhilly reports. Mayor Nutt... |
| - | 4 ways pharma can deal with the unknowns of Obamacare | One of the biggest challenges pharmaceutical manufacturers face in trying to establish compliance with the Affordable Care Act (ACA) is uncertainty. With so many details of the 906-page legislation still undefined and awaiting final guidanc... |
| - | 15 things you should know about the final rule of the Physician Payment Sunshine Act | Back on December 19, 2011, CMS solicited public comment on the Physician Payment Sunshine Act, and in response, it received 373 comments. Since then pharmaceutical and medical device manufacturers have been waiting for the final rule, and l... |
Show more